crygene.

What's new in bioscience — research, preprints, clinical trials, funding and company moves. Global, with an India filter. Nothing here is hand-picked: the site collects and sorts itself, every day.

Updated · 160 items

Research

40

Peer-reviewed papers. Global items come only from a whitelist of 46 core journals — a new paper has no citations, so where it published is the only quality signal available on day one. India-affiliated work uses a wider net, because the local ecosystem mostly does not publish in Nature.

Preprints

30

bioRxiv and medRxiv — where new biology often lands months before the journal version. Not peer reviewed. Filtered on subject relevance, not quality, because no quality signal exists yet.

Trials

40

Phase 2 and 3 interventional studies from ClinicalTrials.gov. Note the real limit: Indian trials mostly register with CTRI, not CT.gov — so "India" here means a global study running Indian sites, which is where global pharma touches India. A CTRI reader is the next addition.

Industry & funding

50

Rounds, approvals, launches and company moves from 13 trade and business feeds. Specialist bioscience outlets pass through; general business feeds have to earn their place on a keyword in the headline.